Antioxidative and Anti-Inflammatory Potentials of Ambroxol in Ameliorating Vincristine Induced Peripheral Neuropathic Pain in Rats

Bhardwaj HC*, Muthuraman A, Hari KSL and Navis S
Rayat Bahra University, India

*Corresponding author: Hukkam Chand Bhardwaj, Rayat Bahra University, India, Tel: 1605009665; E-mail: bhardwaj21003@gmail.com

Abstract

The present study was designed to investigate the ameliorative potential of Ambroxol, a voltage gated sodium channel 1.8 (VGSC 1.8) inhibitor in Vincristine induced neuropathic pain in rats. Administration with Vincristine (75 µg/mg, intraperitoneal) for 10 consecutive days induces neuropathic pain. Hyperalgesia and allodynic symptoms were assessed with various behavioral models i.e., paw thermal-heat hyperalgesia, tail cold hyperalgesia and paw cold allodynia via hot-plate test, cold-water tail immersion test and acetone drop test at different time intervals of 0, 1, 7, 14, and 21 days. Oxidative stress markers i.e., thiobarbituric acid reactive substances, superoxide anion content and inflammatory mediators like tumor necrosis factor-alpha and myeloperoxidase were biochemically assessed from sciatic nerve tissue and surrounding muscular tissue homogenates respectively. Pharmacological co-treatments with Ambroxol (1000 mg/kg, per oral), Carbamazepine (100 mg/kg, per oral) and combination of Ambroxol with Pregabalin (10 mg/kg, per oral) for 14 days, significantly ameliorate the Vincristine induced neuropathic pain in terms of attenuating paw thermal hyperalgesia, tail-cold hyperalgesia and paw cold allodynia along with decrease in oxidative stress markers and inflammatory mediators. Therefore, on the basis of data in hand from present study, it has been concluded that Ambroxol have neuroprotective potential in ameliorating Vincristine induced neuropathic pain in rats.

Keywords: Vincristine induced neuropathic pain; Hyperalgesia; Alldynia; Sciatic nerve; Oxidative stress; TNF-alpha; Myeloperoxidase

Introduction

Neuropathic pain is a persistent chronic pain resulting from damage to the central or peripheral pain signaling pathways [1]. Neuropathic pain is typically characterized by sensory abnormalities such as Hyperalgesia (Increased pain perception/response to painful stimuli), allodynia (pain in response to stimuli that doesn’t normally provoked pain) and dysesthesia (Unpleasant abnormal sensation) [2,3]. Neuropathic pain is a symptomatic condition and not a disease which is caused by various disorders or dysfunctioning of somatosensory components of nervous system [4]. Recent definition of neuropathic pain proposed by International consensus and adopted by International Association for Standardization of Pain (IASP) is ‘Pain arising as a direct consequence of a lesion or disease affecting the somatosensory system’ [5,6].

Neuropathic pain can be caused by several factors such as infections, trauma, metabolic abnormalities, chemotherapy, surgery, radiation, neurotoxins, nerve compression, inflammation and tumor invasion [2,7]. It is difficult to diagnose and distinguish neuropathic pain from other pain types [8]. Chemotherapy induced peripheral neuropathic pain is most common and toxic neurological complication and is observed in about 30-40% patients treated with antineoplastic agents [9,10]. Vincristine, a vinca alkaloid is a widely used antineoplastic drug that is used alone or in a combination with other drugs for the treatment of many tumor types [10-13]. Vincristine induces dose dependent peripheral neuropathic pain [11,13,14] that occur in two major stages. In early stage, Vincristine damages the peripheral axons and produces the symptoms like paresthesias and dysesthesias. At higher doses in the later stage, axons are lost that result into loss of motor functions. Vincristine also increases oxidative stress and calcium levels [15]. Systemic administration of Vincristine (100 µg/kg) by intra venous route for 2 week period, produced hyperalgesia that persists for more than one week after the last injection of Vincristine. Vincristine (100 µg/kg/day) administration resulted into central sensitization of spinal wide dynamic range (WDR) neurons which contributes to hyperalgesia in patients and hyper-responsiveness to sensory stimuli in animals [13]. Also, Vincristine (75 µg/kg) by intra peritoneal route for 10 consecutive days (5 days/week) significantly produced neuropathic pain assessed by different behavioral models for hyperalgesia and allodynia. Moreover, Vincristine (75 µg/kg) significantly increase oxidative stress and inflammatory markers [16]. Vincristine binds to microtubules and causes morphological changes in Vincristined and unmyelinated fibers and these morphological changes contribute to hyperalgesia in rats and paresthesias and dysesthesias in patients. Vincristine is highly sensitive to peripheral neurons and does not cross the blood-brain barrier [17].

Materials and Methods

Experimental animals

The experimental animals Sprague Dawley rats weighing 180-250 grams, employed in the present research study were purchased from National Institute of Pharmaceutical Education and Research (NIPER) S.A.S. Nagar Mohali (India), were maintained on standard laboratory diet (Ashirwaad Feeds Ltd., Kharar, Chandigarh, India) and having free access to tap water. They were housed in the Rayat and Bahra Institute of Pharmacy departmental animal house and were exposed to normal cycle of light and dark. The experimental protocol (RBIP/IAEC/CPCSEA PROTOCOL NO. 11) was approved by the
Institutional Animal Ethics Committee (IAEC) and the care of the animals was carried out as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India (Reg. No-1380/a/10/CPCSEA).

Drugs and chemicals

Vincristine sulfate injections (1 mg/ml) were purchased from post graduate institute of medical education and research (PGIMER) Chandigarh, India. The drugs Ambroxol and Pregabalin were taken as a gift samples from Zee Laboratories Ltd. Poanta Sahib (H.P.), India. All the other chemicals used in present study were of analytical grade.

Treatment schedule

The present study consists of 5 experimental groups and each group comprises of five sprague dawley rats. All the animals were acclimatized to laboratory environment for at least one week before starting experiments. After one week animals were divided into the following groups and respective treatments were given to these groups. All the behavioral testing were carried out two hours prior to any drug treatment.

Induction of neuropathic pain

Peripheral neuropathic pain was induced in rats by injecting Vincristine sulfate 0.075 mg/kg intraperitoneal 5 days per week (for two weeks) as described previously [18] Vincristine sulfate injections were given daily (Monday through Friday) followed by 2 days gap per week.

Behavioral examinations

The experimental animals were subjected for various behavioral studies for assessment of hyperalgesia and allodynia carried out on the different time intervals of 0,1,7,14 and 21 days.

Paw thermal hyperalgesia (Hot Plate Test)

Thermal hyperalgesia (noxious thermal stimuli) of the hind paw was assessed using Eddy's hot plate as described by method of Eddy [19]. The temperature of the plate was maintained 52.5 ± 0.5°C. The rats were placed on the top of a controlled preheated plate to assess the withdrawal response of hind paw to the nociceptive threshold. The cut-off times of 20 seconds was maintained for thermal hyperalgesia.

Paw cold allodynia (Acetone Drop Method)

Cold allodynia were assessed using the acetone drop method as described by Choi et al. and Muthuraman et al., [20]. Rats were placed on wire mesh grid and 0.1 ml (100 μl) of acetone was sprayed with the help of plastic syringe on plantar surface of hind paw. Normal rats either ignored the stimulus or occasionally responded with a small and brief withdrawal of hind paw. Responses with respect to either paw licking, shaking or rubbing the hind paw was observed and recorded as paw lifting duration. The cut off time was 20 seconds.

Tail cold hyperalgesia (Tail Immersion Test)

The cold hyperalgesia was assessed by using tail immersion in cold water as described by Necker [21]. The terminal tip (1 cm) of tail was immersed in cold water (temperature maintained 0-4°C). The withdrawal latency of tail from cold water was recorded. The cut off time for cold water tail immersion test was taken as 20 seconds.

Biochemical estimations

All experimental animals were sacrificed at the end of experiment by cervical dislocation. The sciatic nerve and the muscular tissue beneath the sciatic nerve were located and isolated immediately. Isolated sciatic nerve was excised into small pieces and the uniform sciatic nerve homogenates were prepared with 0.1 M Tris-HCl buffer (pH 7.4) and phosphate buffer (pH 7.4). The test tubes with homogenate were kept in ice water for 30 minutes and centrifuged at 4°C (2500 rpm, 10 min). The supernatants of homogenates were separated, and employed to estimate superoxide anion generation [22], total protein [23], thio-barbituric acid reactive substances [24], and tumor necrosis factor-alpha (TNF-α) respectively. Also, homogenate of surrounding muscular tissue was prepared with phosphate buffer (pH 7.4) for myeloperoxidase (MPO) activity [25].

Estimation of tissue total protein

Total protein content in sciatic nerve was determined by Lowry's method [23] using bovine serum albumin (BSA) as a standard. The protein content was determined spectrophotometrically at 750 nm and expressed as mg per ml of 10% sciatic nerve homogenate.

Estimation of superoxide anion generation

The superoxide anion generation was measured by Wang [22] method. A weighed amount of tissue was taken in 5 ml phosphate buffered saline containing 100 μM of nitro-blue tetrazolium (NBT) and incubated at 37°C for 1.5 hours. The reduction of NBT was stopped by adding 5 ml of 0.5 M HCl. Then, the tissue was taken out and was minced and homogenized in a mixture of 0.1 M sodium hydroxide and 0.1% sodium dodecyl sulphate in water containing 40 mg/L diethylene triamine penta acetic acid. Then mixture was centrifuged at 20,000 rpm for 20 min and the resultant pellet was suspended in 1.5 ml of pyridine and kept at 80°C for 1.5 hours to extract formazan (an adduct formed after reaction of NBT with superoxide anions). The mixture was again centrifuged at 10,000 rpm for 10 min and absorbance of formazan was determined spectrophotometrically at 540 nm. The amount of reduced NBT was calculated using the formula

\[
\text{Amount of reduced NBT} = A \times V / [T] \times W_t \times \varepsilon \times L
\]

Where A is absorbance, V is volume of pyridine (1.5 ml), T is time for which thawed tissue was incubated with NBT (1.5 hours), Wt is wooled wet weight of tissue (mg), ε is extinction coefficient (0.72 L/mmol/mm) and l is length of light path (1 cm). Results were expressed as reduced NBT picomole per min per mg of wet tissue.

Estimation of thio-barbituric acid reactive substances

The lipid peroxidation in the sciatic nerve was estimated by measuring the thio-barbituric acid reactive substances method of Ohkawa et al., [24] The reaction mixture was prepared by mixing 0.2 ml of sciatic nerve homogenate, 0.2 ml of 8.1% sodium dodecyl sulphate (SDS), 1.5 ml of 20% acetic acid solution adjusted to pH 3.5 with NaOH, and 1.5 ml of 0.8% aqueous solution of thio-barbituric acid (TBA). The reaction mixture was made up to 4.0 ml with distilled water, and then heated in water bath at 95°C for 60 min. After cooling with tap water, 1.0 ml of distilled water and 5.0 ml of mixture of n-butanol and pyridine (15:1 v/v) were added to reaction mixture and
shaken vigorously. After centrifugation at 4000 rpm for 10 min, the
organic layer was separated out and its absorbance at 532 nm was
measured. TBARS level (MDA concentrations) were calculated from
the standard curve of 1,1,3,3-tetramethoxypropane (TMP).

Estimation of myeloperoxidase activity

Myeloperoxidase (MPO) activity was measured as described by
Grisham et al., [25]. The presence of MPO was measured at 460 nm for
3 minutes. MPO activity is expressed as U per g tissue. One unit of
MPO activity is defined as that degrading 1 μmol peroxide per min at
25°C. The results were expressed as myeloperoxidase activity units per
milligram of protein at one minute.

Estimation of tumor necrosis factor-alpha (TNF-α) level

Sciatic nerve samples were utilized for determination of TNF-α
level. TNF-α levels (sensitivity: 25 pg/ml) were determined by using rat
TNF-alpha ELISA kit and procedure was followed according to the
manufacturer instructions. Sciatic nerve homogenate was prepared
with phosphate buffer (pH 7.4). Recombinant anti-Rat TNF-alpha was
used as a standard to generate a standard curve. The absorbance was
measured spectrophotometrically at 450 nm. The results were
expressed as picograms of TNF-α per mg of protein.

Experimental protocol

Group 1: Normal group - Animals of this group were not subjected to
any treatment. They were kept for 21 days. Behavioral tests were
assessed on different time intervals, i.e., 0, 1, 7, 14 and 21st day. All the
animals were sacrificed and subjected to biochemical estimations of
total protein, tumor necrosis factor-alpha (TNF-α), thio-barbituric acid
reactive substances (TBARS), superoxide anion generation from sciatic
nerve tissue and myeloperoxidase (MPO) activity in the surrounding
muscular tissue sample.

Group 2: Vincristine control group - Animals of this group were treated
with Vincristine sulfate injections 75 μg/kg intraperitoneal 5
days per week for 10 days. All the behavioral tests and biochemical
parameters were assessed as mentioned in group I.

Group 3: Vincristine + Ambroxol treated group - Animals of this
group were treated with Ambroxol 1000 mg/kg, per oral for
consecutive 14 days before 60 minutes prior to Vincristine injection.
All the behavioral tests and biochemical parameters were assessed as
mentioned in group I.

Group 4: Vincristine + Carbamazepine treated group - Animals of
this group were treated with Carbamazepine 100 mg/kg, peroral and
Pregabalin 10 mg/kg peroral for consecutive 14 days before each
Vincristine injection. All the behavioral tests and biochemical
parameters were assessed as mentioned in group I.

Group 5: Vincristine + Ambroxol + Pregabalin treated group - Animals
of this group were treated with Ambroxol 1000 mg/kg, peroral and
Pregabalin 10 mg/kg peroral for consecutive 14 days before each
Vincristine injection. All the behavioral tests and biochemical
parameters were assessed as mentioned in group I.

Statistical analysis

All the result values were expressed as mean ± S.E.M. The data of
behavioral results and biochemical parameters were statistically
analyzed by two way analysis of variance (ANOVA) followed by
Bonferroni’s post-hoc test and Tukey’s multiple comparison test
respectively using Graph Pad Prism version-6.0 and Graph Pad-Instat
softwares. Results having probability value P ≤ 0.05 were considered as
statistically significant.

Results

Effect of Ambroxol, Carbamazepine and combination of
Ambroxol with Pregabalin on paw thermal hyperalgesia

Vincristine administration significantly resulted into development
of thermal heat hyperalgesia assessed by hot plate test. Vincristine
produces a significant decrease in the nociceptive threshold for
thermal conduction heat hyperalgesia as reflected by decrease in paw
withdrawal threshold, when compared to normal group. Treatment
with Ambroxol (1000 mg/kg, peroral) and Carbamazepine (100 mg/kg,
peroral) significantly attenuated Vincristine induced decrease in the
noxious nociceptive threshold for thermal conduction heat
hyperalgesia and the ameliorative effect of Ambroxol in attenuating
Vincristine induced decrease in paw withdrawal threshold was
significantly comparable to the Carbamazepine. Similar effects were
observed in Ambroxol with Pregabalin (10 mg/kg, p.o.) treated rats
(Figure 1).

Effect of Ambroxol, Carbamazepine and combination of
Ambroxol with Pregabalin on tail cold hyperalgesia

Tail cold hyperalgesia was assessed by cold water tail-immersion test
(0–4°C). Vincristine administration was associated with the
development of tail cold hyperalgesia as reflected by decrease in tail
withdrawal threshold to cold water (0–4°C), when compared to normal
group. Vincristine administration for two weeks decreased tail
withdrawal duration. Pharmacological treatments with Ambroxol
(1000 mg/kg, peroral) and Carbamazepine (100 mg/kg, peroral)
significantly attenuated the tail cold allodynia to cold stimuli. Effect of
Ambroxol in attenuating tail withdrawal duration was significantly
comparable to the Carbamazepine. Similar effects were observed in
Ambroxol with Pregabalin (10 mg/kg, peroral) treated rats (Figure 2).

Citation: Bhardwaj HC, Muthuraman A, Hari KSL, Navis S (2016) Antioxidative and Anti-Inflammatory Potentials of Ambroxol in Ameliorating

ISSN:2314-7334 JNID an open access journal

Volume 7 • Issue 1 • 1000202
Effect of Ambroxol, Carbamazepine and combination of Ambroxol with Pregabalin on biochemical parameters

Vincristine administration was associated with an increase in the oxidative stress markers i.e, thio-barbituric acid reactive substances, superoxide anion generation and inflammatory mediators like myeloperoxidase and tumor necrosis factor-alpha in the sciatic nerve tissue, when compared to the normal control group (Figures 4-7). However, pharmacological co-treatments with Ambroxol (1000 mg/kg peroral) and Carbamazepine (100 mg/kg peroral) significantly (p ≤ 0.05) prevent Vincristine induced increase in oxidative stress markers and inflammatory mediators when compared to Vincristine control group. Similar effects were observed in Ambroxol with Pregabalin treated rats (Table 1).

neurotoxicities and development of peripheral neuropathic pain. Though, there is no specific pharmacological class of drugs for treating neuropathic pain, but clinically available other classes of drugs are being potentially effective in providing symptomatic relief from acute as well as chronic painful neuropathies. Some antidepressants, antiepileptics and opioid analgesics are found to be clinically effective as single or in combinational therapy with other drugs in the management of neuropathic pain, but their full clinical exploitation is limited due to their life threatening adverse effects associated with their clinical use [15,26,27]. Moreover, none of the medication has been found clinically effective in chemotherapy induced neuropathic pain. Therefore, there have been an urgent need of alternative medicines for the management of chemotherapy induced neuropathic pain. The present study has been designed to explore the possible therapeutic and preventive management of chemotherapy induced neuropathic pain.

Chronic administration of Vincristine for two weeks resulted into development of painful behaviors such as paw thermal hyperalgesia, tail cold hyperalgesia and paw cold allodynia in experimental animals. An increased level or overproduction of oxidative stress and inflammatory biomarkers in peripheral nerve tissues has also been reported that resulted into oxidative damage to neuronal cells and neuro-inflammation to peripheral nerves. An increased level of thiobarbituric acid reactive substances (TBARS), superoxide anion generation, tumor necrosis factor-alpha (TNF-α) and myeloperoxidase were biochemically estimated in the present study, confirming the pathophysiological role of oxidative stress and neuro-inflammation in Vincristine induced peripheral neuropathic pain. Present results revealed that ameliorative potential of current pharmacological treatments is due to attenuating chemotherapy induced painful behaviors, reducing oxidative stress and neuro-inflammation in peripheral neuronal tissues.

Previous some studies revealed that oxidative stress play a key pathophysiological role in the pathogenesis of Vincristine induced peripheral painful neuropathy. Various studies has been focused on oxidative stress as a major target in Vincristine induced neuropathic pain [1,15,28]. Also, many antioxidants therapies ameliorate chemotherapy induced oxidative stress in the development of neuropathic pain. Beside, oxidative stress, neuro-inflammation is also an important pathophysiological marker in the pathogenesis of Vincristine induced neuropathic pain. Development of painful behaviors and biochemical alterations, in present study are in consistent with the earlier researches [1,15,28]. Chronic administration of Vincristine resulted into increase in tumor necrosis factor-alpha that play a crucial pathophysiological role in the pathogenesis of inflammatory and neuropathic pain. An increased TNF-α level in sciatic nerve tissue were reported in Vincristine induced neuropathic models [15,18,28].

Discussion

Vincristine is a well-known antineoplastic drug clinically used from last 3 or 4 decades for the treatment of cancer but associated with

<table>
<thead>
<tr>
<th>Experimental Groups</th>
<th>TBARS protein (nmol/mg of protein)</th>
<th>Superoxide Anion Content (pmol/min/mg of wet tissue)</th>
<th>Myeloperoxidase Activity (U/min/mg of protein)</th>
<th>Tumor Necrosis Factor-α (TNF-α) (pg/mg of protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Group</td>
<td>3.61 ± 0.05</td>
<td>30.80 ± 0.35</td>
<td>10.48 ± 0.27</td>
<td>3.40 ± 0.19</td>
</tr>
<tr>
<td>Vin Control</td>
<td>8.11 ± 0.08 a</td>
<td>50.53 ± 0.15 a</td>
<td>102.70 ± 2.99 a</td>
<td>9.67 ± 0.08 a</td>
</tr>
<tr>
<td>Vin + Ambroxol</td>
<td>5.11 ± 0.05 a,b,c</td>
<td>38.77 ± 0.17 a,b,c</td>
<td>29.27 ± 0.88 a,b,c</td>
<td>5.52 ± 0.97 a,b,c</td>
</tr>
</tbody>
</table>
References

10. Geis C, Beyreuther BK, Stohr T, Sommer C (2011) Lacosamide has neuroprotective properties: a back translation of Pregabalin and Carbamazepine against thio-barbituric acid substances (TBARS), superoxide anion content, myeloperoxidase (MPO) activity and tumor necrosis factor-alpha (TNF-α) in Vincristine induced peripheral neuropathic pain. Values were expressed as mean ± S.E.M; n=5 rats per group. One-way ANOVA followed by Dunnett’s multiple comparison test, a=p ≤ 0.05 vs normal control, b=p ≤ 0.05 vs Vincristine control group, c=p ≤ 0.05 vs Carbamazepine treated group and ns=p>0.05 represent having no significance.

Table 1: Effect of Ambroxol, Carbamazepine and combination of Ambroxol with Pregabalin on thio-barbituric acid substances (TBARS), superoxide anion content, myeloperoxidase (MPO) activity and tumor necrosis factor-alpha (TNF-α) in Vincristine induced peripheral neuropathic pain.

<table>
<thead>
<tr>
<th></th>
<th>Vin</th>
<th>Carbamazepine</th>
<th>Vin (Amb + Carb)</th>
<th>Vin (Amb + Preg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect</td>
<td>6.16 ± 0.07 a,b</td>
<td>44.57 ± 0.28 a.b</td>
<td>50.76 ± 0.71 a,b</td>
<td>8.67 ± 0.12 a.b</td>
</tr>
</tbody>
</table>


